8-K
filed July 8, 2024, 7:59 PM ET
ticker XERS
CIK 0001867096
leadership
confidence high
sentiment positive
materiality 0.85
Xeris CEO Paul Edick steps down; John Shannon named CEO; Q2 revenue >$47M (+23% YoY)
Xeris Biopharma Holdings, Inc.
- CEO Paul R. Edick transitions to Senior Advisor effective Aug 1, 2024; John Shannon (President & COO) appointed new CEO and Board member.
- Marla S. Persky appointed Chairperson of the Board effective Aug 1, 2024.
- Preliminary Q2 2024 total revenue exceeds $47.0M, representing >23% growth over prior year.
- Year-end 2024 cash guidance reaffirmed at $55M to $75M.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Paul R. Edick resigned as Chairman of the Board at Xeris Biopharma Holdings, Inc..
- Action
- resigned
- Role
- Chairman of the Board
Exact text from the filing
On July 8, 2024, the Company announced that, effective August 1, 2024 (the “Transition Date”), Paul R. Edick will transition from his role as Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”) and will become a Senior Advisor to the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John Shannon was appointed as Class III Director at Xeris Biopharma Holdings, Inc..
- Action
- appointed
- Role
- Class III Director
Exact text from the filing
The Board also approved the appointment of Mr. Shannon as a Class III director, effective as of the Transition Date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Paul R. Edick resigned as Chief Executive Officer at Xeris Biopharma Holdings, Inc..
- Action
- resigned
- Role
- Chief Executive Officer
Exact text from the filing
On July 8, 2024, the Company announced that, effective August 1, 2024 (the “Transition Date”), Paul R. Edick will transition from his role as Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”) and will become a Senior Advisor to the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Marla S. Persky was appointed as Chairperson of the Board at Xeris Biopharma Holdings, Inc..
- Action
- appointed
- Role
- Chairperson of the Board
Exact text from the filing
Marla S. Persky, currently a Class III director of the Company, has been appointed by the Board to serve as the Chairperson of the Board, effective as of the Transition Date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John Shannon was appointed as Chief Executive Officer at Xeris Biopharma Holdings, Inc..
- Action
- appointed
- Role
- Chief Executive Officer
Exact text from the filing
John Shannon, currently the Company’s President and Chief Operating Officer, has been appointed by the Board to serve as the Company’s Chief Executive Officer, effective as of the Transition Date.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.